Surrozen, Inc. — Form 8-K Summary
Filing date: July 30, 2021. The filing was submitted by Consonance-HFW Acquisition Corp. in connection with its proposed business combination with Surrozen, Inc. It is a transaction and listing update, not a periodic financial report.
Business Context and Reporting Period
- Consonance-HFW determined, subject to closing of the Business Combination, to voluntarily withdraw its common stock, warrants, and units from NYSE American.
- The post-combination company is expected to list its common stock and warrants on The Nasdaq Global Select Market under the symbols SRZN and SRZNW.
- Trading on Nasdaq was expected to begin at market open on or about August 12, 2021; the final NYSE American trading date was expected to be on or about August 11, 2021.
- The SEC declared the Form S-4 registration statement effective on July 15, 2021. A special meeting of Consonance-HFW shareholders was scheduled for August 10, 2021 to consider the Business Combination and related matters.
Financial Metrics and Capitalization
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, valuation, redemption amounts, or other operating financial metrics. It states that the definitive proxy statement/final prospectus contains relevant pro forma financial information.
Material Changes Versus the Prior Comparable Period
No comparable-period financial results are presented. The material development is the planned exchange listing transition associated with the proposed Business Combination.
Guidance, Outlook, Risks, and Unusual Items
- Completion of the Business Combination remained subject to required approvals and other closing conditions; the filing did not confirm consummation.
- Forward-looking statements addressed the anticipated benefits and opportunities of the combined company, but no quantified financial guidance was provided.
- Identified risks include failure to obtain shareholder approvals, termination or delay of the transaction, legal proceedings, redemption requests, difficulty integrating operations, inability to maintain Nasdaq listing, costs of the transaction, retention of key employees, and failure to achieve anticipated benefits.
- The filing also noted risks related to SEC accounting and reporting considerations for warrants issued by special purpose acquisition companies.
- The press release regarding the exchange listing was furnished as Exhibit 99.1 under Regulation FD and was not deemed filed for purposes of Section 18 of the Exchange Act.
Investor Verification Items
- Verify whether the Business Combination ultimately closed and the conditions and approvals required at closing.
- Review the Form S-4 and definitive proxy statement for pro forma financial information, transaction terms, dilution, redemption assumptions, and capitalization.
- Confirm whether the post-combination securities began trading on Nasdaq under SRZN and SRZNW and whether listing requirements were maintained.
- Assess the final number of shares and warrants issued, cash remaining after redemptions, and transaction-related costs.
- Review subsequent filings for Surrozen’s operating results, liquidity, financing needs, clinical-development risks, and updated outlook.